Figure 2. Experimental Schematic. The CBA mice were randomly assigned into 5 groups. Group1 (n=10): to receive daily subcutaneous injection of saline for 5 days and one intracranial injection of saline (saline); Group 2 (n = 10): to receive daily subcutaneous injection of 20mg/kg MPTP (Sigma-Aldrich, St. Louis, MO, USA) for 5 days and one intracranial injection of saline (MPTP); Group 3 (n = 10): to receive daily subcutaneous injection of 20mg/kg MPTP for 5 days, one intracranial injection of saline and daily ECT treatment (an electrical current of 80 mC (80 mA, 50 Hz, 1s duration and 0.5ms pulse width) through ear clip electrodes) for 8 days (MPTP+ECT); Group 4 (n = 10): to receive daily subcutaneous injection of 20mg/kg MPTP for 5 days and one intracranial injection of 1012 MSCs from isogeneic mice (MPTP+MSCs); Group 5 (n = 10): to receive daily subcutaneous injection of 20mg/kg MPTP for 5 days, one intracranial injection of 1012 MSCs from isogeneic mice and daily ECT treatment (an electrical current of 80 mC (80 mA, 50 Hz, 1s duration and 0.5ms pulse width) through ear clip electrodes) for 8 days (MPTP+ECT+MSCs). All the mice were kept for another 2 months, and then subjected to rational behavior test, stepping test for assessing behavioral disorder. Afterwards, the mice were sampled for analyzing histology and signaling to dissect underlying mechanisms.